Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
AssigneeAllergan, Inc.
InventorsKei Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
Life of this patent
Estimating the term…
Abstract
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Claims30
A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component of a Botulinum toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from a single Botulinum toxin type to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons, and wherein said Botulinum toxin is Botulinum toxin type B.
A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from only a Botulinum toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a Botulinum toxin type B, thereby reducing the severity of an abnormal head position symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a Botulinum toxin type B, thereby reducing a neck pain symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
Dependencies are inferred from the claim text.